Key Highlights
- Loss per share was USD 8.51 against an estimate of a USD 5.68 loss.
- Research and development expense was USD 18.13 million, against USD 5.01 million.
- Cash and cash equivalents were USD 87.7 million at September 30.
- The board approved a plan to separate the CRHX-101 program into Adrenyx.
Spruce Biosciences (NASDAQ:SPRB) reported a third quarter 2026 loss per share of USD 8.51, against an estimate of a USD 5.68 loss and a USD 14.58 loss in the third quarter of 2025. The company reported the figures in its quarterly filing for the period ended September 30, 2026.
Net loss was USD 24.01 million. The loss from operations was USD 23.98 million, compared with USD 8.23 million a year earlier. The company says it focuses on diseases with high unmet medical need and clear biology, where there are either no approved therapies for the underlying disease or suboptimal treatment options. Total operating expenses were USD 23.98 million, against USD 8.23 million.
Operating Expenses and Interest
Research and development expense was USD 18.13 million, compared with USD 5.01 million, and general and administrative expense was USD 5.85 million, compared with USD 3.22 million. For the nine months, total operating expenses were USD 52.48 million, against USD 25.41 million.
Interest expense increased by USD 1.2 million for the quarter, and by USD 2.9 million for the nine months, due to an increase in the company's debt. Interest and other income, net, increased by USD 0.7 million for the quarter and USD 1.4 million for the nine months.
The nine-month loss per share was USD 23.71, compared with USD 41.25 in the same period of 2025. The filing also notes that the change in Fair Value of Warrant and conversion option liabilities increased by USD 0.5 million for the quarter and USD 0.4 million for the nine months.
Separation of the CRHX-101 Program
On November 6, 2026, the board approved a plan to separate and contribute the CRHX-101 program into Adrenyx. On the same day, the company and Adrenyx entered into a series of agreements, including a separation and distribution agreement and a transition services agreement.
The filing states that approval by stockholders is not required as a condition to completing the distribution, and that there can be no assurance the distribution is completed on the anticipated timeline, on the anticipated terms or at all.
Liquidity
As of September 30, 2026, the company had cash and cash equivalents of USD 87.7 million, compared with USD 48.91 million at December 31, 2025. The filing states that, without alternative financing or proceeds from other strategic alternatives, and based on its current operating plan, this amount is insufficient to fund its planned operations and Debt obligations for at least 12 months following the issuance date of the financial statements.
Spruce Biosciences Q3 2026 Earnings: Key Takeaways
Spruce Biosciences reported a third quarter 2026 loss per share of USD 8.51 and Research and Development expense of USD 18.13 million. Cash and cash equivalents were USD 87.7 million, and the board approved a plan to separate the CRHX-101 program into Adrenyx.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...